115 related articles for article (PubMed ID: 7380909)
1. Quantitation of the antitumor agent N-(phosphonacetyl)-L-aspartic acid in human plasma and urine by gas chromatography-mass spectrometry-selected ion monitoring.
Branfman AR; Bruni RJ; Merrill YN; Chadwick M; Strong JM; Ervin TJ
J Chromatogr; 1980 May; 182(2):163-9. PubMed ID: 7380909
[TBL] [Abstract][Full Text] [Related]
2. Determination of N-(Phosphonacetyl)-L-aspartic acid (PALA) in dog serum and urine by gas chromatography and selected lon monitoring.
Strong JM; Kinney YE; Branfman AR; Cysyk RL
Cancer Treat Rep; 1979 May; 63(5):775-80. PubMed ID: 455314
[TBL] [Abstract][Full Text] [Related]
3. Determination of N-(phosphonacetyl)-L-aspartic acid (PALA) in plasma and urine by high pressure liquid chromatography.
Lankelma J; Penders PG; Leyva A; Pinedo HM
Eur J Cancer (1965); 1980 Nov; 16(11):1483-7. PubMed ID: 7227423
[No Abstract] [Full Text] [Related]
4. Mass spectrometric technique for the determination of N-phosphonoacetyl-L-aspartic acid in serum.
Roboz J; Suzuki R; Rose E
J Chromatogr; 1980 Feb; 181(2):195-205. PubMed ID: 7372753
[TBL] [Abstract][Full Text] [Related]
5. A facile enzymatic technique for the estimation of nanomolar concentrations of N-phosphonacetyl-L-aspartic acid in plasma.
Kensler TW; Jayaram HN; Cooney DA
J Biochem Biophys Methods; 1980; 2(1):29-35. PubMed ID: 6999068
[TBL] [Abstract][Full Text] [Related]
6. Application of a simple competitive protein-binding assay technique to the pharmacokinetics of N-(phosphonacetyl)-L-aspartate in humans.
Erlichman C; Strong JM; Chabner BA
Cancer Res; 1980 Jun; 40(6):1902-6. PubMed ID: 7371023
[TBL] [Abstract][Full Text] [Related]
7. Comparative physiological disposition of N-(phosphonacetyl)-L-aspartate in several animal species after intravenous and oral administration.
Chadwick M; Silveira DM; MacGregor JA; Branfman AR; Liss RH; Yesair DW
Cancer Res; 1982 Feb; 42(2):627-32. PubMed ID: 7055806
[TBL] [Abstract][Full Text] [Related]
8. Enzymatic assay for the antitumor agent-N-(phosphonacetyl)-L-aspartic acid (PALA).
Friedman J; Moore EC; Hall SW; Loo TL
Cancer Treat Rep; 1979 Jan; 63(1):85-8. PubMed ID: 421235
[TBL] [Abstract][Full Text] [Related]
9. An enzymatic technique for measuring N-phosphonacetyl-L-aspartic acid in tissues.
Cooney DA; Karlowicz MG; Cubillan J; Roettger M; Jayaram HN
Cancer Treat Rep; 1978 Oct; 62(10):1503-7. PubMed ID: 361225
[TBL] [Abstract][Full Text] [Related]
10. Long-term association of N-(phosphonacetyl)-L-aspartate with bone.
Ardalan B; Kensler TW; Jayaram HN; Morrison W; Choie DD; Chadwick M; Liss R; Cooney DA
Cancer Res; 1981 Jan; 41(1):150-6. PubMed ID: 7448755
[TBL] [Abstract][Full Text] [Related]
11. Concentrations of N-(phosphonacetyl)-L-aspartate (PALA) in plasma and tears in man.
Lankelma J; Penders PG; Leyva A; Kleeberg UR; Kenny JB; Bramwell V; McVie JG; Pinedo HM
Eur J Cancer Clin Oncol; 1981 Nov; 17(11):1199-204. PubMed ID: 7199467
[No Abstract] [Full Text] [Related]
12. Pharmacological disposition of N-(phosphonacetyl)-L-aspartate in humans.
Loo TL; Friedman J; Moore EC; Valdivieso M; Marti JR; Stewart D
Cancer Res; 1980 Jan; 40(1):86-90. PubMed ID: 7349907
[TBL] [Abstract][Full Text] [Related]
13. Peripheral leukocytes as indicators of the enzymatic effects of N-(phosphonacetyl)-L-aspartic acid (PALA) on human L-aspartate transcarbamoylase (ATCase) activity.
Kensler TW; Erlichman C; Jayaram HN; Tyagi AK; Ardalan B; Cooney DA
Cancer Treat Rep; 1980; 64(8-9):967-73. PubMed ID: 7448831
[TBL] [Abstract][Full Text] [Related]
14. Plasma uridine changes in cancer patients treated with the combination of dipyridamole and N-phosphonacetyl-L-aspartate.
Chan TC; Markman M; Cleary S; Howell SB
Cancer Res; 1986 Jun; 46(6):3168-72. PubMed ID: 3698032
[TBL] [Abstract][Full Text] [Related]
15. A phase II trial of PALA + dipyridamole in patients with advanced soft-tissue sarcoma.
Casper ES; Baselga J; Smart TB; Magill GB; Markman M; Ranhosky A
Cancer Chemother Pharmacol; 1991; 28(1):51-4. PubMed ID: 2040033
[TBL] [Abstract][Full Text] [Related]
16. Embryotoxicity in mice of phosphonacetyl-L-aspartic acid (PALA), a new antitumor agent. I. Embryolethal, teratogenic, and cytogenetic effects.
Sieber SM; Botkin CC; Soong P; Lee EC; Whang-Peng J
Teratology; 1980 Dec; 22(3):311-9. PubMed ID: 7233336
[TBL] [Abstract][Full Text] [Related]
17. Penetration of N-(phosphonacetyl)-L-aspartate into human central nervous system and intracerebral tumor.
Stewart DJ; Leavens M; Friedman J; Benjamin RS; Moore EC; Bodey GP; Valdivieso M; Burgess MA; Wiseman C; Loo TL
Cancer Res; 1980 Sep; 40(9):3163-6. PubMed ID: 7427934
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of N-phosphonacetyl-L-aspartic acid in combination with nitrobenzylthioinosine.
Erlichman C; Vidgen D
Biochem Pharmacol; 1984 Oct; 33(20):3177-81. PubMed ID: 6487365
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of N-(Phosphonacetyl)-L-aspartic acid (PALA).
Ervin TJ; Blum RH; Meshad MW; Kufe DW; Johnson RK; Canellos GP
Cancer Treat Rep; 1980; 64(10-11):1067-71. PubMed ID: 7459892
[TBL] [Abstract][Full Text] [Related]
20. Phase II evaluation of N-(phosphonacetyl)-L-aspartic acid (PALA) in patients with non-small cell carcinoma of the lung.
Casper ES; Gralla RJ; Kelsen DP; Houghton A; Golbey RB; Young CW
Cancer Treat Rep; 1980; 64(4-5):705-7. PubMed ID: 6448688
[No Abstract] [Full Text] [Related]
[Next] [New Search]
